Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease

Jung Eun Cho, Jin Kim

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuropathological features comprising amyloid deposits and neuronal losses in brain. In AD, aggregation of a β-amyloid peptide (Aβ), produced from proteolytic cleavage of amyloid precursor protein, is believed to be implicated in the pathophysiological cascade leading to neuronal death. Most AD drugs currently available can only alleviate symptoms rather than modify the underlying molecular cause of AD. In this review, we describe and discuss the recent patents issued within the past two years focusing on therapeutic interventions targeting at various Aβ-associated pathological mechanisms of AD. The described therapeutic strategies include 1) reduction of synthesis of Aβ, 2) inhibition of Aβaggregation, 3) immunotherapeutic/enzymatic clearance of Aβ, 4) targeting other amyloidogenic proteins interacting with Aβand 5) amelioration of Aβdownstream toxic effects. Important issues to be considered for further improvement of therapeutic efficacy of these approaches are also discussed.

Original languageEnglish (US)
Pages (from-to)222-233
Number of pages12
JournalRecent Patents on CNS Drug Discovery
Volume6
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Amyloid
Alzheimer Disease
Amyloidogenic Proteins
Therapeutics
Patents
Amyloid beta-Protein Precursor
Poisons
Amyloid Plaques
Neurodegenerative Diseases
Brain
Pharmaceutical Preparations

Keywords

  • Aggregation
  • Alpha synuclein
  • Alzheimer's disease
  • Amyloid
  • Antibody
  • Beta amyloid
  • Tau

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease. / Cho, Jung Eun; Kim, Jin.

In: Recent Patents on CNS Drug Discovery, Vol. 6, No. 3, 09.2011, p. 222-233.

Research output: Contribution to journalArticle

@article{888f2b966f2e4597ab3c8c6eae496378,
title = "Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuropathological features comprising amyloid deposits and neuronal losses in brain. In AD, aggregation of a β-amyloid peptide (Aβ), produced from proteolytic cleavage of amyloid precursor protein, is believed to be implicated in the pathophysiological cascade leading to neuronal death. Most AD drugs currently available can only alleviate symptoms rather than modify the underlying molecular cause of AD. In this review, we describe and discuss the recent patents issued within the past two years focusing on therapeutic interventions targeting at various Aβ-associated pathological mechanisms of AD. The described therapeutic strategies include 1) reduction of synthesis of Aβ, 2) inhibition of Aβaggregation, 3) immunotherapeutic/enzymatic clearance of Aβ, 4) targeting other amyloidogenic proteins interacting with Aβand 5) amelioration of Aβdownstream toxic effects. Important issues to be considered for further improvement of therapeutic efficacy of these approaches are also discussed.",
keywords = "Aggregation, Alpha synuclein, Alzheimer's disease, Amyloid, Antibody, Beta amyloid, Tau",
author = "Cho, {Jung Eun} and Jin Kim",
year = "2011",
month = "9",
doi = "10.2174/157488911796958002",
language = "English (US)",
volume = "6",
pages = "222--233",
journal = "Recent Patents on CNS Drug Discovery",
issn = "1574-8898",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease

AU - Cho, Jung Eun

AU - Kim, Jin

PY - 2011/9

Y1 - 2011/9

N2 - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuropathological features comprising amyloid deposits and neuronal losses in brain. In AD, aggregation of a β-amyloid peptide (Aβ), produced from proteolytic cleavage of amyloid precursor protein, is believed to be implicated in the pathophysiological cascade leading to neuronal death. Most AD drugs currently available can only alleviate symptoms rather than modify the underlying molecular cause of AD. In this review, we describe and discuss the recent patents issued within the past two years focusing on therapeutic interventions targeting at various Aβ-associated pathological mechanisms of AD. The described therapeutic strategies include 1) reduction of synthesis of Aβ, 2) inhibition of Aβaggregation, 3) immunotherapeutic/enzymatic clearance of Aβ, 4) targeting other amyloidogenic proteins interacting with Aβand 5) amelioration of Aβdownstream toxic effects. Important issues to be considered for further improvement of therapeutic efficacy of these approaches are also discussed.

AB - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuropathological features comprising amyloid deposits and neuronal losses in brain. In AD, aggregation of a β-amyloid peptide (Aβ), produced from proteolytic cleavage of amyloid precursor protein, is believed to be implicated in the pathophysiological cascade leading to neuronal death. Most AD drugs currently available can only alleviate symptoms rather than modify the underlying molecular cause of AD. In this review, we describe and discuss the recent patents issued within the past two years focusing on therapeutic interventions targeting at various Aβ-associated pathological mechanisms of AD. The described therapeutic strategies include 1) reduction of synthesis of Aβ, 2) inhibition of Aβaggregation, 3) immunotherapeutic/enzymatic clearance of Aβ, 4) targeting other amyloidogenic proteins interacting with Aβand 5) amelioration of Aβdownstream toxic effects. Important issues to be considered for further improvement of therapeutic efficacy of these approaches are also discussed.

KW - Aggregation

KW - Alpha synuclein

KW - Alzheimer's disease

KW - Amyloid

KW - Antibody

KW - Beta amyloid

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=80052234053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052234053&partnerID=8YFLogxK

U2 - 10.2174/157488911796958002

DO - 10.2174/157488911796958002

M3 - Article

VL - 6

SP - 222

EP - 233

JO - Recent Patents on CNS Drug Discovery

JF - Recent Patents on CNS Drug Discovery

SN - 1574-8898

IS - 3

ER -